Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Sonveaux P, Brouet A, Havaux X, et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res. 2003;63(5):1012–1019.
   PubMed Web of Science ®Google Scholar
• Chen FH, Chiang CS, Wang CC, et al. Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy. Int J Radiat Oncol Biol Phys. 2011;80(5):1512–1521.
   PubMed Web of Science ®Google Scholar
• He Y, Cao Y. VEGF and tumor angiogenesis and its application on anti-tumor drug exploration. Chinese Bulletin Of Life Sciences. 2008;20(2):222–224.
   Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019.
   Google Scholar
• Fan Y, Yu Z, Huo X, et al. Efficacy of recombinant human endostatin combined with chemoradiotherapy in the treatment of cervical cancer. Chinese Remedies & Clinics. 2017;17(6):865–868.
   Google Scholar
• Ke QH, Zhou SQ, Huang M, et al. Early efficacy of endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev. 2012;13(3):923–926.
   PubMedGoogle Scholar
• Liu X, Hou B, Song X, et al. The efficacy of Endostar combined with co-chemoradiotherapy for stage ? bulky cervical cancer. Journal of Logistics University of Cape. 2013;22(3):178–181.
   Google Scholar
• Lu H, Wu Y, Liu X, et al. Endostar, an antiangiogenesis inhibitor, combined with chemoradiotherapy for locally advanced cervical cancer. Oncol Res. 2022;28(9):929–944.
   PubMed Web of Science ®Google Scholar
• Rao L, Xia C, Xie Z, et al. Clinical efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of advanced cervical cancer. Anti-Tumor Pharmacy. 2018;8(5):767–771.
   Google Scholar
• Ren Y, Yang C. Clinical study of apatinib combined with radiotherapy and chemotherapy in the treatment of advanced cervical cancer. J of China Prescription Drug. 2020;18(11):120–122.
   Google Scholar
• Shu H, Dong Y, Xu Z, et al. The efficacy and safety of continuous intravenous endostar treatment combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma: a randomized controlled trial. Front Oncol. 2021;11:723193.
   PubMed Web of Science ®Google Scholar
• Tang Y, Wei Q, Xu X. Effect of recombinant human endostatin on sensitization of radiotherapy in cervical cancer. Chinese Journal of Postgraduates of Medicine. 2021;44(1):67–71.
   Google Scholar
• Wang X, Chen L, Zhang H, et al. Recombinant human endostatin combined with concurrent radiochemotherapy in the treatment of 56 cases of advanced cervical cancer. Jilin Med J. 2021;42(8):1812–1815.
   Google Scholar
• Wu T. Recombinant human endostatin in combination with chemoradiotherapy in patients with locally advanced cervical cancer. 2019.
   Google Scholar
• Xu Y, Xiao H, Jiang S, et al. The clinical efficacy and safety of Apatinib combined with radiotherapy and chemotherapy in the patients with medium-and late-stage cervical cancer. Chinese Journal of Geriatrics. 2021;40(9):1165–1168.
   Google Scholar
• Zhao FJ, Su Q, Zhang W, et al. Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients. World J Clin Cases. 2021;9(27):8061–8070.
   PubMed Web of Science ®Google Scholar
• Hu X, Wang J, Chang J, et al. Shanghai expert consensus on diagnosis and treatment of cancer pain. China Oncology. 2017;27(4):312–319.
   Google Scholar
• Dueñas-González A, Cetina-Perez L, Lopez-Graniel C, et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study. Int J Radiat Oncol Biol Phys. 2005;61(3):817–823.
   PubMed Web of Science ®Google Scholar
• Wang X, Gu Y, Liu H, et al. Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells. Onco Targets Ther. 2018;11:1245–1258.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654–1663.
   PubMed Web of Science ®Google Scholar
• Jackson MW, Rusthoven CG, Fisher CM, et al. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther. 2014;7:751–759. Published 2014 May 16.
   PubMed Web of Science ®Google Scholar
• Jia Z, Yang Y, Zhang S, et al. Value of vascular endothelial growth factor to the diagnosis of various malignancies. Journal of Chinese Practical Diagnosis and Therapy. 2015;29(7):701–702,705.
   Google Scholar
• Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer [published correction appears in. N Engl J Med. 2017 Aug 17;377(7):702]. N Engl J Med. 2014;370(8):734-743.
   Google Scholar
• Datta NR, Rogers S, Klingbiel D, et al. Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses. Int J Hyperthermia. 2016;32(7):809–821.
   PubMed Web of Science ®Google Scholar
• Liu GF, Chang H, Li BT, et al. Effect of recombinant human endostatin onradiotherapy for esophagus cancer. Asian Pac J Trop Med. 2016;9(1):86–90.
   PubMed Web of Science ®Google Scholar
• Li X, Pan Y, Qin L, et al. Inhibitory effect of AuNPs-Endostar on melanoma lung metastasis in mice. Chinese Journal of Pathophysiology. 2017;33(8):1393–1398.
   Google Scholar
• Schefter T, Winter K, Kwon JS, et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014;88(1):101–105.
   PubMed Web of Science ®Google Scholar
• Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872–880.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients.[J].Annals of oncology. Official Journal of the European Society for Medical Oncology. 2009;20(5):807–881.
   PubMed Web of Science ®Google Scholar